| pubmed-article:20143438 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20143438 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:20143438 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:20143438 | lifeskim:mentions | umls-concept:C0555198 | lld:lifeskim |
| pubmed-article:20143438 | lifeskim:mentions | umls-concept:C0061465 | lld:lifeskim |
| pubmed-article:20143438 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:20143438 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:20143438 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:20143438 | lifeskim:mentions | umls-concept:C0994515 | lld:lifeskim |
| pubmed-article:20143438 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:20143438 | pubmed:dateCreated | 2010-3-29 | lld:pubmed |
| pubmed-article:20143438 | pubmed:abstractText | : Glioma cells secrete glutamate and also express alpha-amino-3-hydroxy-5 methyl-4-isoxazolepropionate (AMPA) glutamate receptors, which contribute to the proliferation, migration, and neurotoxicity of malignant gliomas. Talampanel is an oral AMPA receptor inhibitor with excellent central nervous system penetration and good tolerability in clinical trials for epilepsy and other neurologic disorders. | lld:pubmed |
| pubmed-article:20143438 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20143438 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:20143438 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20143438 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20143438 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:20143438 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:20143438 | pubmed:author | pubmed-author:ButmanJohn... | lld:pubmed |
| pubmed-article:20143438 | pubmed:author | pubmed-author:FineHoward... | lld:pubmed |
| pubmed-article:20143438 | pubmed:author | pubmed-author:AlbertPaul... | lld:pubmed |
| pubmed-article:20143438 | pubmed:author | pubmed-author:IwamotoFabio... | lld:pubmed |
| pubmed-article:20143438 | pubmed:author | pubmed-author:KimLyndonL | lld:pubmed |
| pubmed-article:20143438 | pubmed:author | pubmed-author:DuicJ PaulJP | lld:pubmed |
| pubmed-article:20143438 | pubmed:author | pubmed-author:KreislTeri... | lld:pubmed |
| pubmed-article:20143438 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20143438 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20143438 | pubmed:volume | 116 | lld:pubmed |
| pubmed-article:20143438 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20143438 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20143438 | pubmed:pagination | 1776-82 | lld:pubmed |
| pubmed-article:20143438 | pubmed:dateRevised | 2011-9-29 | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:meshHeading | pubmed-meshheading:20143438... | lld:pubmed |
| pubmed-article:20143438 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20143438 | pubmed:articleTitle | Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. | lld:pubmed |
| pubmed-article:20143438 | pubmed:affiliation | Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. | lld:pubmed |
| pubmed-article:20143438 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20143438 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
